structural basis kynurenine monooxygenase inhibition
inhibition kynurenine monooxygenase kmo enzyme eukaryotic tryptophan catabolic pathway kynurenine pathway leads amelioration huntingtons-disease-relevant phenotypes yeast fruitfly mouse models- well mouse model alzheimers disease kmo flavin adenine dinucleotide fad-dependent monooxygenase located outer mitochondrial membrane converts l-kynurenine hydroxykynurenine perturbations levels kynurenine pathway metabolites linked pathogenesis spectrum brain disorders well cancer several peripheral inflammatory conditions despite importance kmo target neurodegenerative disease molecular basis kmo inhibition available lead compounds remained unknown report first crystal structure saccharomyces cerevisiae kmo free form complex tight-binding inhibitor upf upf binds close fad cofactor perturbs local active-site structure preventing productive binding substrate l-kynurenine functional assays targeted mutagenesis reveal active-site architecture upf binding essentially identical human kmo validating yeast kmo-upf structure template structure-based drug design will inform search new kmo inhibitors able cross blood-brain barrier targeted therapies neurodegenerative diseases huntingtons alzheimers parkinsons diseases
